A1-2: Cost-Effectiveness of Interleukin 28B Genotype-Guided Protease Inhibitor Therapy in Treatment-Naïve Patients with Hepatitis C Virus Genotype 2 or 3

BACKGROUND/AIMS: The addition of protease inhibitors to standard of care (SOC) dramatically increases treatment response in Hepatitis C Virus (HCV) genotype 1 patients. Moreover, Interleukin 28B (IL28B) genotyping helps predict responsiveness for these patients. However, the economic implications of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bock, Jonathan, Fairley, Kimberly, Smith, Robert, Maeng, Daniel, Pitcavage, James, Inverso, Nicholas, Williams, Marc
Formato: Artigo
Idioma:Inglês
Publicado em: Marshfield Clinic 2013
Assuntos:
Selected Abstracts-HMORN 2013: Comparative Effectiveness Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3788547/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3121/cmr.2013.1176.a1-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados